Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. On March 27, 2020, durvalumab was approved by the FDA for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab is indicated for the treatment of adults with the following conditions:
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Honor Health, Scottsdale, Arizona, United States
Johns Hopkins University, Baltimore, Maryland, United States
Oregon Health and Science University, Portland, Oregon, United States
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Gustave Roussy, Villejuif, Val De Marne, France
National University Hospital, Singapore, Singapore
Raffles Hospital, Singapore, Singapore
Singapore General Hospital, Singapore, Singapore
M D Anderson Cancer Center, Houston, Texas, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.